ONCOLYTICS BIOTECH-Wert mit Potential
| eröffnet am: | 10.02.13 00:51 von: | Heron |
| neuester Beitrag: | 24.04.21 23:58 von: | Ulrikesbyva |
| Anzahl Beiträge: | 236 | |
| Leser gesamt: | 53366 | |
| davon Heute: | 8 | |
bewertet mit 8 Sternen |
||
|
|
||
03.04.17 16:33
#226
Lao-Tse
Respekt
Oncy, ich persönlich war der Meinung, dass es noch etwas dauert. Schade!
03.04.17 21:04
#228
Cobra7
coole News
schönes Vol. leider wird das aber abverkauft, da noch das ATM-Programm läuft und KE wird bestimmt kommen.
schöne Gewinne bis jetzt sind es trotzdem, glückwunsch an alle :-)
alles aussem Annual Report
We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the Base Shelf) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the Securities)
On February 25, 2016, we entered into a new ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million.........
During 2016, we sold 3,006,600 common shares for gross proceeds of $1,456,296.
http://www.oncolyticsbiotech.com/wp-content/..._Annual_Report_web.pdf
schöne Gewinne bis jetzt sind es trotzdem, glückwunsch an alle :-)
alles aussem Annual Report
We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the Base Shelf) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the Securities)
On February 25, 2016, we entered into a new ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million.........
During 2016, we sold 3,006,600 common shares for gross proceeds of $1,456,296.
http://www.oncolyticsbiotech.com/wp-content/..._Annual_Report_web.pdf
08.05.17 13:55
#231
Cobra7
Zahlen
von freitag
Financial
At March 31, 2017, the Company reported $10.1 million in cash, cash equivalents and short-term investments.
As at May 4, 2017, the Company had an unlimited number of authorized common shares with 121,836,722 common shares issued and outstanding, and 8,032,827 options outstanding (with exercise prices ranging between $0.26 and $6.72 and expiry dates ranging from 2017 to 2027).
http://www.oncolyticsbiotech.com/news/...-2017-first-quarter-results/
Financial
At March 31, 2017, the Company reported $10.1 million in cash, cash equivalents and short-term investments.
As at May 4, 2017, the Company had an unlimited number of authorized common shares with 121,836,722 common shares issued and outstanding, and 8,032,827 options outstanding (with exercise prices ranging between $0.26 and $6.72 and expiry dates ranging from 2017 to 2027).
http://www.oncolyticsbiotech.com/news/...-2017-first-quarter-results/
24.05.17 17:25
#232
Cobra7
Da
Ist die KE doch ;-) wie erwartet
Oncolytics Bio prices equity offering; shares down 19% https://seekingalpha.com/news/3269615?source=ansh $ONCYF
Ist die KE doch ;-) wie erwartet
Oncolytics Bio prices equity offering; shares down 19% https://seekingalpha.com/news/3269615?source=ansh $ONCYF
01.06.17 16:01
#233
skate
...was heißt das jetzt im Klartext?
Sie bieten 1 Aktie für 0,70 zu Verkauf an?
11.01.18 10:53
#236
skate
Ja, das riecht lecker :)
Ich würde in 2018 alles unter 0,67 als günstig sehen...
und ab 0,5 als Leckerbissen...
alles darunter ...
klingt nach echt heißer Schokolade mit Kirschen... gibt's leider sehr, sehr selten...
und ab 0,5 als Leckerbissen...
alles darunter ...
klingt nach echt heißer Schokolade mit Kirschen... gibt's leider sehr, sehr selten...